Draft Guidance for Industry on Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics; Availability

 
Docket ID: FDA-2011-D-0432
Agency: Food and Drug Administration (FDA)
Parent Agency: Department of Health and Human Services (HHS)
Docket Details open glossary dialog  
Related RINs: None
Related Dockets: None
Short Title: Draft Guidance for Industry on Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics; Availability
Keyword(s): CDER20102, Drugs and Biologics, Lung Cancer, Non-Small Cell, Clinical Trial Endpoints, 2013-600, Approval, Guidance for Industry, Availability, Open
Type: Nonrulemaking
Docket Status: OPEN
Center: CDER
Docket Item Code: D
 

Primary Documents

View All  (4)
Comment Period Closed
Aug 16, 2011 11:59 PM ET
Notice
Posted: 06/17/2011
ID: FDA-2011-D-0432-0001
Comment Period Closed
Aug 16, 2011 11:59 PM ET
Other
Posted: 06/17/2011
ID: FDA-2011-D-0432-0002
Comment Period Closed
Notice
Posted: 04/22/2015
ID: FDA-2011-D-0432-0013

Supporting Documents

 
No documents available.

Comments

View All  (10)

10
Comments Received*
*This count refers to the total comment/submissions received on this docket, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. This can result in discrepancies between this count and those displayed when conducting searches on the Public Submission document type. For specific information about an agency’s public submission policy, refer to its website or the Federal Register document.